Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Akros Pharma Inc.
Age
18–75
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Subjects with end stage renal disease on hemodialysis
Post-dialysis body weight \>45.0 kg
BMI between 18.0 and 40.0 kg/m2 (inclusive)
You may not be if
Subjects with aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \>2.0 × upper limit of normal (ULN), or total bilirubin \>1.5 × ULN at the Screening Visit
Subjects who have hepatobiliary disease or condition (such as biliary cirrhosis)
Subjects with positive test results for HBsAg (hepatitis B surface antigen), HCV antibody or HIV antibody
Subjects with known history of liver failure or liver surgery
Subjects with a history or current clinically significant chronic or acute blood loss
Clareo Health | Mass Balance Study of JTZ-951 in Subjects With End-stage Renal Disease on Hemodialysis
